UBS Lowers Enhabit Price Target to $8.50 from $10, Maintains Neutral Rating
PorAinvest
domingo, 10 de agosto de 2025, 6:53 am ET1 min de lectura
EHAB--
Home health services saw admissions grow by 1.3% year over year, while hospice care delivered its sixth consecutive quarter of growth with an average daily census rising by 12.3%. The company also strengthened its balance sheet by reducing bank debt and increasing liquidity. Enhabit opened three de novo locations, including one home health and two hospice facilities, and continued its de-levering efforts, reducing bank debt by $10.0 million in the quarter.
However, UBS has recently lowered the price target for Enhabit to $8.50 from $10, maintaining a Neutral rating. The analyst highlighted the ongoing challenges facing the home health industry, including rate cuts, and advised caution. Enhabit is focused on addressing these issues, but the analyst noted that the company's efforts to mitigate the impact of rate cuts may take time to materialize.
Enhabit's financial performance for the second quarter was robust, with strong growth in revenue and Adjusted EBITDA. However, the company faces significant challenges in the home health industry, particularly concerning rate cuts. Investors should closely monitor the company's efforts to address these challenges and the impact on its financial performance.
References:
[1] https://www.businesswire.com/news/home/20250805819765/en/Enhabit-Reports-Second-Quarter-2025-Financial-Results
UBS--
UBS has lowered the price target for Enhabit (EHAB) to $8.50 from $10 and maintains a Neutral rating. The Q2 results were positive, but the company is focused on addressing the home health rate cut. The analyst highlights the ongoing challenges facing the home health industry and advises caution.
Enhabit, Inc. (NYSE: EHAB), a leading provider of home health and hospice care, reported its second-quarter 2025 financial results, showcasing a positive performance despite industry challenges. The company reported net service revenue of $266.1 million, net income of $5.2 million, and Adjusted EBITDA of $26.9 million for the quarter ended June 30, 2025. These results reflect strong execution of strategic priorities, with sequential and year-over-year growth in revenue and Adjusted EBITDA.Home health services saw admissions grow by 1.3% year over year, while hospice care delivered its sixth consecutive quarter of growth with an average daily census rising by 12.3%. The company also strengthened its balance sheet by reducing bank debt and increasing liquidity. Enhabit opened three de novo locations, including one home health and two hospice facilities, and continued its de-levering efforts, reducing bank debt by $10.0 million in the quarter.
However, UBS has recently lowered the price target for Enhabit to $8.50 from $10, maintaining a Neutral rating. The analyst highlighted the ongoing challenges facing the home health industry, including rate cuts, and advised caution. Enhabit is focused on addressing these issues, but the analyst noted that the company's efforts to mitigate the impact of rate cuts may take time to materialize.
Enhabit's financial performance for the second quarter was robust, with strong growth in revenue and Adjusted EBITDA. However, the company faces significant challenges in the home health industry, particularly concerning rate cuts. Investors should closely monitor the company's efforts to address these challenges and the impact on its financial performance.
References:
[1] https://www.businesswire.com/news/home/20250805819765/en/Enhabit-Reports-Second-Quarter-2025-Financial-Results

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios